Italy News Board

The Pizzeria of News

Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.

Leave a Reply

Your email address will not be published. Required fields are marked *